Market Cap
$2.4B
NRIX
Nurix Therapeutics, Inc.
$22.86 ▼ -2.06%
Prev close $23.34Market cap$2.4B
ConsensusStrong Buy
12-mo target$33.93 (+48.4%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)26 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on NRIX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (90%)
Inst. Holders
50 funds
Inst. Value
$1.6B
Inst. Activity
26 buys / 16 sells
Insider Activity
$0.00 buy / $2.8M sell
Insider Net $
-$2.8M
SEC Reports
16
Press Releases
2
Price chart 30d -11.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 7, 2026 earnings_calendar
Sep 2, 2026 SEC NRIX Q3 2026 Earnings Scheduled — 2026-10-07
Two C-suite insiders at Nurix Therapeutics (NRIX) — Chief Scientific Officer Gwenn Hansen and Chief Legal Officer Christ
CLUSTER — Impact 2/10
Sep 2, 2026 Insider
Ring Christine sold 400 shares
Chief Legal Officer @ $26.64 ($10.7K)
Sep 2, 2026 Insider
Ring Christine sold 5,387 shares
Chief Legal Officer @ $25.69 ($138.4K)
Sep 2, 2026 Insider
Aug 5, 2026 SEC Ring Christine acquired via exercise 5,787 shares
Chief Legal Officer @ $8.72 ($50.5K)
Three C-suite insiders at Nurix Therapeutics (NRIX) sold a total of $534K in open-market shares over a 7-day window, wit
CLUSTER — Impact 3/10
Three C-suite insiders at Nurix Therapeutics (CSO, CLO, CFO) sold a total of $461K in open-market shares over a 7-day wi
CLUSTER — Impact 2/10
Jun 30, 2026 Inst.
Rubric Capital Management LP — DOUBLED
7,227,778 shares ($175.3M)
Analyst ratings buy % -1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
90% rate it Buy or better · 21 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 10, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Aug 4, 2026 | Needham | REITERATE | Buy | 50% |
| Jul 28, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Jul 22, 2026 | UBS | MAINTAIN | Buy | 55% |
| Jul 13, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jul 10, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Jul 10, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jul 10, 2026 | Stifel | MAINTAIN | Buy | 54% |
| Jul 10, 2026 | BTIG | REITERATE | Buy | 53% |
| Jul 10, 2026 | Needham | REITERATE | Buy | 50% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 12 | 2 | 0 | 0 | 90% | |
| Aug 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Jul 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Jun 1, 2026 | 8 | 14 | 1 | 0 | 0 | 96% | |
| May 1, 2026 | 8 | 14 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 8 | 14 | 1 | 0 | 0 | 96% | |
| Mar 1, 2026 | 8 | 14 | 1 | 0 | 0 | 96% | |
| Feb 1, 2026 | 8 | 14 | 1 | 0 | 0 | 96% |
Price targets
Where 14 covering analysts think NRIX trades over the next 12 months.
$33.93 +48.4% upside Strong Buy
Current$22.86 Low$25.00 Median$34.00 High$45.00 14 analysts
$25.00$45.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 2 bullish, 2 bearish, 0 mixed, 12 neutral · avg impact 3.7/10.Plus 2 press releases.
NEUTRALCLUSTER2/10
Two C-suite insiders at Nurix Therapeutics (NRIX) — Chief Scientific Officer Gwenn Hansen and Chief
Sep 2, 2026
NEUTRALCLUSTER3/10
Three C-suite insiders at Nurix Therapeutics (NRIX) sold a total of $534K in open-market shares over
Aug 5, 2026
NEUTRALCLUSTER2/10
Three C-suite insiders at Nurix Therapeutics (CSO, CLO, CFO) sold a total of $461K in open-market sh
Aug 5, 2026
NEUTRALCLUSTER3/10
Three C-suite insiders at Nurix Therapeutics (CFO, CSO, CLO) sold a total of ~$515K in open-market s
Aug 5, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 7, 2026
earnings_calendar
NRIX Q3 2026 Earnings Scheduled — 2026-10-07
Sep 17, 2026
short_volume
Short Volume: NRIX — 56.6% short (0.4M / 0.7M)
Short: 399,911 | Exempt: 0 | TRF Vol: 706,751 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
Sep 11, 2026
short_volume
Short Volume: NRIX — 63.6% short (0.4M / 0.6M)
Short: 365,349 | Exempt: 0 | TRF Vol: 574,858 | Short Ratio: 63.6% | Off-exchange volume (dark pool + OTC)
Aug 4, 2026
other
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated
Jul 21, 2026
contract
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $5.11 | $4.29–$5.74 | 596.5% | +0.0% | 2↑ 0↓ | $0.5B | 3 |
| Next Q | $-0.37 | $-0.64–$-0.11 | 55.0% | +0.0% | 2↑ 0↓ | $0.3B | 3 |
| Current FY | $3.38 | $3.03–$3.82 | 210.7% | +88.9% | 2↑ 1↓ | $0.8B | 3 |
| Next FY | $-1.07 | $-1.83–$-0.68 | -131.5% | +26.0% | 3↑ 0↓ | $0.1B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $5.114 | — |
| 7d ago | $5.114 | — |
| 30d ago | $5.114 | — |
| 60d ago | $-0.697 | +5.811 |
| 90d ago | $-0.737 | +5.851 |
Institutional ownership
Which big funds own NRIX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.6B total value (67,069,813 shares) as of 2026-Q2. Top holders: NOMURA, BlackRock,, Rubric. Net buying activity: 26 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| BlackRock, Inc. | 8,770,349 | $212.8M | 13.1% | — |
| Rubric Capital Management LP | 7,227,778 | $175.3M | 10.8% | DOUBLED +192.2% |
| FMR LLC | 5,485,215 | $133.1M | 8.2% | ADD +30.9% |
| MORGAN STANLEY | 4,762,484 | $115.5M | 7.1% | — |
| STATE STREET CORP | 4,677,244 | $113.5M | 7.0% | ADD +44.4% |
| BAKER BROS. ADVISORS LP | 4,658,556 | $113.0M | 6.9% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,495,529 | $109.1M | 6.7% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,537,291 | $61.6M | 3.8% | — |
| Pictet Asset Management Holding SA | 2,351,232 | $57.0M | 3.5% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Rubric Capital Management LP | DOUBLED | 2,473,885 | 7,227,778 | +192.2% | $175.3M |
| Capital World Investors | DOUBLED | 893,327 | 1,787,916 | +100.1% | $43.4M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 1,102,266 | 1,482,861 | +34.5% | $36.0M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 780,696 | 1,431,317 | +83.3% | $34.7M |
| GOLDMAN SACHS GROUP INC | TRIM | 1,318,659 | 813,589 | -38.3% | $19.7M |
| RAYMOND JAMES FINANCIAL INC | ADD | 353,733 | 593,262 | +67.7% | $14.4M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEW | — | 477,141 | — | $11.6M |
| Candriam S.C.A. | TRIM | 534,259 | 377,902 | -29.3% | $9.2M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | TRIM | 620,820 | 363,603 | -41.4% | $8.8M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 223,363 | 340,578 | +52.5% | $8.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 50 transactions. Net -$2.8M — $0.00 bought, $2.8M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Ring Christine | Chief Legal Officer | SELL | 400 | $26.64 | $10.7K |
| Sep 2, 2026 | Ring Christine | Chief Legal Officer | SELL | 5,387 | $25.69 | $138.4K |
| Sep 2, 2026 | Ring Christine | Chief Legal Officer | EXERCISE | 5,787 | $8.72 | $50.5K |
| Sep 1, 2026 | Hansen Gwenn | Chief Scientific Officer | SELL | 1,452 | $25.47 | $37.0K |
| Sep 1, 2026 | Hansen Gwenn | Chief Scientific Officer | EXERCISE | 1,452 | $1.86 | $2.7K |
| Aug 5, 2026 | Hansen Gwenn | Chief Scientific Officer | EXERCISE | 4,356 | $1.86 | $8.1K |
| Aug 5, 2026 | Hansen Gwenn | Chief Scientific Officer | SELL | 4,356 | $25.00 | $108.9K |
| Aug 4, 2026 | van Houte Hans | Chief Financial Officer | SELL | 1,794 | $23.89 | $42.9K |
| Aug 4, 2026 | van Houte Hans | Chief Financial Officer | SELL | 2,967 | $24.65 | $73.1K |
| Aug 4, 2026 | Hansen Gwenn | Chief Scientific Officer | SELL | 1,500 | $23.87 | $35.8K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NRIX.
Shares short
17,976,804
Settlement Sep 15, 2026
Change vs prior
+0.1%
Semi-monthly cycle
Days to cover
14.1
At avg daily volume
Of shares outstanding
≈17.3%
Estimate — not % of float
All NRIX filing & press-release reports (18)
- CLUSTER reportSep 2, 2026
- CLUSTER reportAug 5, 2026
- CLUSTER reportAug 5, 2026
- CLUSTER reportAug 5, 2026
- CLUSTER reportAug 3, 2026
- CLUSTER reportJul 30, 2026
- PRESS-RELEASE reportJul 9, 2026
- CLUSTER reportJul 2, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 8, 2026
- PRESS-RELEASE reportJun 8, 2026
- CLUSTER reportMay 5, 2026
- CLUSTER reportMay 4, 2026
- CLUSTER reportMay 1, 2026
- CLUSTER reportApr 30, 2026
- PRESS-RELEASE reportApr 22, 2026
- PRESS-RELEASE reportApr 21, 2026
- 8-K reportApr 8, 2026